Evidence map›Paper›PMID 30823446›Full record

ReviewNutrients2019

Beta-Aminoisobutyric Acid as a Novel Regulator of Carbohydrate and Lipid Metabolism.

Dmitrii A Tanianskii, Natalia Jarzebska, Andreas L Birkenfeld, John F O'Sullivan, Roman N Rodionov

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 2 syntheses or guidelines pooled it, 122 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Effects of fasting and inflammatory challenges on the swine hepatic metabolome.Comparative biochemistry and physiology. Part D, Genomics & proteomics · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Fecal Microbiome and Urine Metabolome Profiling of Type 2 Diabetes.Journal of microbiology and biotechnology · 2025
    Article
  18. Review
  19. Synthesis of (1,10-Phenanthroline-Molecules (Basel, Switzerland) · 2025
    Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Dmitrii A TanianskiiDepartment of Biochemistry, Institute of Experimental Medicine, Acad. Pavlov St., 12, 197376 St. Petersburg, Russia. dmitry.athero@gmail.com.ORCID 0000-0002-5321-8834
Natalia JarzebskaUniversity Center for Vascular Medicine, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany. natalia.jarzebska@uniklinikum-dresden.de.
Andreas L BirkenfeldMedical Clinic III, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany. andreas.birkenfeld@uniklinikum-dresden.de.
John F O'SullivanMedical Clinic III, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany. john.osullivan@sydney.edu.au.
Roman N RodionovUniversity Center for Vascular Medicine, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany. Roman.Rodionov@uniklinikum-dresden.de.
Technische Universität Dresden · DESt Petersburg University · RUThe University of Sydney · AU

Funding

Deutscher Akademischer Austauschdienst 57210733
6 · The paper itself

Abstract

The prevalence and incidence of metabolic syndrome is reaching pandemic proportions worldwide, thus warranting an intensive search for novel preventive and treatment strategies. Recent studies have identified a number of soluble factors secreted by adipocytes and myocytes (adipo-/myokines), which link sedentary life style, abdominal obesity, and impairments in carbohydrate and lipid metabolism. In this review, we discuss the metabolic roles of the recently discovered myokine β-aminoisobutyric acid (BAIBA), which is produced by skeletal muscle during physical activity. In addition to physical activity, the circulating levels of BAIBA are controlled by the mitochondrial enzyme alanine: glyoxylate aminotransferase 2 (AGXT2), which is primarily expressed in the liver and kidneys. Recent studies have shown that BAIBA can protect from diet-induced obesity in animal models. It induces transition of white adipose tissue to a "beige" phenotype, which induces fatty acids oxidation and increases insulin sensitivity. While the exact mechanisms of BAIBA-induced metabolic effects are still not well understood, we discuss some of the proposed pathways. The reviewed data provide new insights into the connection between physical activity and energy metabolism and suggest that BAIBA might be a potential novel drug for treatment of the metabolic syndrome and its cardiovascular complications.

Indexed as

Aminoisobutyric AcidsAnimalsCarbohydrate MetabolismEnergy MetabolismHumansLipid MetabolismMuscle, Skeletal3-aminoisobutyric acidAminoisobutyric AcidsAGXT2AMPKBAIBAinsulin resistancemetabolic syndromemyokinesobesityPPARs

Identifiers

PMID30823446
PMCPMC6470580
OpenAlexW2917191057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.